Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

125.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,713
Open 125.26
Bid (Size) 126.95 (3)
Ask (Size) 127.00 (30)
Prev. Close 125.26
Today's Range 125.26 - 125.26
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.41%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Why Novo Nordisk Topped the Market Today
It's not only spending its capital on developing new drugs. 
Via The Motley Fool

Performance

YTD
+22.67%
+22.67%
1 Month
-2.94%
-2.94%
3 Month
+18.74%
+18.74%
6 Month
+28.97%
+28.97%
1 Year
+46.95%
+46.95%

More News

Read More
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Via Benzinga
MarketBeat Week in Review – 4/15 - 4/19
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
Via InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Powell And The Great Indecision
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Via The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
NYSE:NVO is showing good growth, while it is not too expensive.
Via Chartmill
Viking Therapeutics: Strong Results In Obesity
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.